Acolbifene

Drug Profile

Acolbifene

Alternative Names: Acolbifene hydrochloride; EM 652.HCl; EM-652; SCH 57068; SCH 57068.HCl

Latest Information Update: 09 Oct 2015

Price : $50

At a glance

  • Originator Endoceutics
  • Developer Endoceutics; National Cancer Institute (USA)
  • Class Antineoplastics; Osteoporosis therapies
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 09 Oct 2015 No recent reports on development identified - Phase-II for Breast cancer (Prevention) in USA (PO)
  • 23 Jul 2015 Acolbifene is available for licensing as of 23 Jul 2015. http://www.endoceutics.com
  • 23 Jul 2015 Further phase III development for Breast cancer is pending as Endoceutics seeks a partner for out-licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top